MB Funds invests in Pharmatory, a Finnish contract development and manufacturing company (“CDMO”) specializing in small molecule active pharmaceutical ingredients (“APIs”), to support expansion of the company. The management of Pharmatory continues to develop the company in their current roles and as significant owners together with MB Funds.
Pharmatory, founded in 2001, provides services for global pharma and biotech companies in medicine development with CDMO offering for human and veterinary pharmaceuticals. The company’s service offering includes analytical, process R&D, and contract manufacturing services according to Good Manufacturing Practice (GMP). The company’s operations are based on long-term partnerships with its clients. Pharmatory has facility in Oulu, Finland, with a team of highly skilled and experienced professionals in the field of chemistry.
“I’m happy to share an important milestone for Pharmatory. We truly welcome MB Funds as an investor and partner. This is more than a financial investment — it is a shared view on what we are building and where we are going. From the very first conversations it was clear that we aligned on vision, ambition, and values. With MB Funds’s experience and support, we are in a strong position to accelerate growth and create even more value for our clients. This investment represents a significant milestone on our 25-year-long journey, and we could not have chosen a better partner for the next phase. Pharmatory remains fully committed to delivering the exceptional quality and client experience in the future too. I’m grateful to everyone who has been part of getting us this far — the best still lies ahead”, states Dr. Jaana Karjalainen, CEO and a founding member of Pharmatory.
With the support of MB Funds, Pharmatory plans to expand its operations into rapidly growing high potency API (“HPAPI”) market by investing in HPAPI facility set-up.
“Pharmatory operates in a highly attractive small molecule API CDMO market and holds a reputation for high scientific know-how, agile client-centric services, quality and effective project management. The company has very capable management with strong experience from international operations and an organization with deep chemistry expertise. Pharmatory is well-positioned to expand into sizeable and rapidly growing high potency API CDMO market, supported by very robust underlying trends, and MB Funds is excited to support company’s growth”, comments Anssi Mattila, partner of MB Funds.
“The investment will focus on construction of a new manufacturing area along with the supporting infrastructure within the existing industrial premises. This enables us to offer a broader spectrum of services, especially for the high potency API GMP manufacturing market, in the near future. The entire Pharmatory team is excited, and we are confident that this collaboration will bring clear benefits to our clients and further enhance the services they have come to rely on over the years. The partnership with MB Funds and the new board members strengthen our journey and give us great support for our next phase of growth”, comments Dr. Heikki Hassila, Business Development Director of Pharmatory.
Pharmatory’s board will be strengthened by Dr. Knut Ringbom, former CEO and one of the founders of Biovian, and Arto Toivonen, M.Sc. (Chem.Eng.), former President of Fermion and Business Development Director of Orion. Ringbom and Toivonen will also become shareholders of Pharmatory together with the management and MB Funds. Anssi Mattila serves as Chair of the Board of Pharmatory, and the other members are Meri Koivula, Knut Ringblom and Arto Toivonen.
***
Additional information:
Anssi Mattila
Partner, MB Funds
+358 50 538 5806 anssi.mattila@mb.fi
Jaana Karjalainen
Toimitusjohtaja, Pharmatory Oy
+358 44 270 7271 jaana.karjalainen@pharmatory.com
